![Min-Chul Park](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Min-Chul Park
Director/Board Member at ZYVERSA THERAPEUTICS, INC.
Net worth: - $ as of 2024-06-29
Min-Chul Park active positions
Companies | Position | Start | End |
---|---|---|---|
ZYVERSA THERAPEUTICS, INC. | Director/Board Member | 2022-11-30 | - |
Independent Dir/Board Member | 2022-11-30 | - | |
ZyVersa Therapeutics Operating, Inc.
![]() ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL. | Director/Board Member | - | - |
Inje University | Corporate Officer/Principal | - | - |
Career history of Min-Chul Park
Former positions of Min-Chul Park
Companies | Position | Start | End |
---|---|---|---|
CURE BIO Co., Ltd.
![]() CURE BIO Co., Ltd. BiotechnologyHealth Technology CURE BIO Co., Ltd. ENGAGES in the research and development of therapeutic and diagnostic products through the use of aminoacyl tRNA synthetase. The company was founded in 2002 and is headquartered in Seoul, South Korea. | Director/Board Member | 2020-09-30 | 2022-03-31 |
Chief Executive Officer | 2020-09-30 | 2022-03-31 | |
Neomics Co., Ltd.
![]() Neomics Co., Ltd. Pharmaceuticals: MajorHealth Technology Neomics Co., Ltd. develops and commercializes diagnostics and therapeutics for human incurable diseases, such as cancer. It provides services of custom antibody and protein production and offers antibody groups including in-house antibodies from aminoacyl-tRNA synthesize. The company was founded by Chi Uk In in 2005 and is headquartered in Seoul, South Korea. | Director/Board Member | - | - |
Chief Executive Officer | - | - |
Training of Min-Chul Park
Seoul National University | Doctorate Degree |
Statistics
International
South Korea | 5 |
United States | 3 |
Operational
Director/Board Member | 5 |
Chief Executive Officer | 3 |
Doctorate Degree | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
ZYVERSA THERAPEUTICS, INC. | Health Technology |
Private companies | 3 |
---|---|
Neomics Co., Ltd.
![]() Neomics Co., Ltd. Pharmaceuticals: MajorHealth Technology Neomics Co., Ltd. develops and commercializes diagnostics and therapeutics for human incurable diseases, such as cancer. It provides services of custom antibody and protein production and offers antibody groups including in-house antibodies from aminoacyl-tRNA synthesize. The company was founded by Chi Uk In in 2005 and is headquartered in Seoul, South Korea. | Health Technology |
ZyVersa Therapeutics Operating, Inc.
![]() ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL. | Health Technology |
CURE BIO Co., Ltd.
![]() CURE BIO Co., Ltd. BiotechnologyHealth Technology CURE BIO Co., Ltd. ENGAGES in the research and development of therapeutic and diagnostic products through the use of aminoacyl tRNA synthetase. The company was founded in 2002 and is headquartered in Seoul, South Korea. | Health Technology |
- Stock Market
- Insiders
- Min-Chul Park
- Experience